Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 702 across all filing types
Latest filing 2015-02-09 Board/Management Inform…
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated February 3, 2015. It reports amendments to the Articles of Incorporation and Bylaws of Flex Pharma, Inc. in connection with the closing of the company's IPO. The content focuses on corporate governance changes, specifically the restated certificate of incorporation and bylaws, and does not contain financial statements or earnings data. It is not an annual or quarterly report, nor an earnings release. The primary subject is changes in corporate governance documents, which aligns with Board/Management Information filings. Therefore, the document is best classified as MANG (Board/Management Information). The document length is under 5,000 characters and contains substantive information about governance changes, not just an announcement or certification, so it is not RPA or RNS.
2015-02-09 English
FORM 4 SUBMISSION
Director's Dealing
2015-02-05 English
FORM 4 SUBMISSION
Director's Dealing
2015-02-04 English
FORM 4 SUBMISSION
Director's Dealing
2015-02-04 English
FORM 4 SUBMISSION
Director's Dealing
2015-02-04 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. It includes detailed information about the securities to be registered, the plans under which they are offered, and legal provisions such as indemnification of directors and officers. This type of filing is related to share issuance and capital changes, specifically the registration of shares for employee stock plans. It is not an annual report, earnings release, or any other financial report but a regulatory filing concerning securities registration under the Securities Act of 1933. According to the filing definitions, announcements or filings about new share issues or capital changes fall under the category 'Share Issue/Capital Change' (SHA). Therefore, the correct classification is SHA with high confidence due to the clear identification of the form and its purpose.
2015-02-02 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.